ProCE Banner Activity

Multidisciplinary Perspectives on Practical Team-Based Application of Newly Available Agents in AML

Case Challenge
Multimedia
Learn how this multidisciplinary team uses the recently approved agents enasidenib, ivosidenib, midostaurin, gemtuzumab ozogamicin, and CPX-351 to provide optimal treatment for patients with acute myeloid leukemia.

Released: August 21, 2018

Expiration: August 20, 2019

No longer available for credit.

Share

Faculty

Farhad Ravandi

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Elizabeth S. Kaled

Elizabeth S. Kaled, NP

Advanced Practice Nurse
Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Deborah A. McCue

Deborah A. McCue, PharmD, BCOP

Manager, Clinical Pharmacy Services
Division of Pharmacy
The University of Texas MD Anderson Cancer Center
Houston, Texas

Mary Alma Welch

Mary Alma Welch, PAC

Manager, Advanced Practice Providers
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Supporters

Agios Pharmaceuticals

Celgene

Learning Objectives

  • Participate in multidisciplinary team–based care considering treatment goals and values of patients with AML
  • Evaluate the clinical data and importance of prognostic or predictive molecular features or aberrations in AML in terms of diagnosis, risk prediction, and prognosis data
  • Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML based on prognosis and predictive molecular features
  • Educate team members and patients regarding new agents for the treatment of AML
  • Discuss the role of clinical pharmacy in optimizing the use of agents recently approved for the treatment of AML, including improving administration and adherence, educating patients, and aiding in the implementation of clinical pathways to deliver quality care
  • Identify and manage treatment-related toxicities associated with agents recently approved for the treatment of AML

Program Director Disclosure

Program Director

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has disclosed that he has received consulting fees from Amgen, Astellas, MacroGenics, and Ordenix and funds for research support from Amgen, Bristol-Myers Squibb, MacroGenics, Ordenix, and Seattle Genetics.

Faculty Disclosure

Primary Author

Elizabeth S. Kaled, NP

Advanced Practice Nurse
Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elizabeth S. Kaled, NP, has no real or apparent conflicts of interest to report.

Deborah A. McCue, PharmD, BCOP

Manager, Clinical Pharmacy Services
Division of Pharmacy
The University of Texas MD Anderson Cancer Center
Houston, Texas

Deborah A. McCue, PharmD, BCOP, has no real or apparent conflicts of interest to report.

Mary Alma Welch, PAC

Manager, Advanced Practice Providers
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Mary Alma Welch, PAC, has no real or apparent conflicts of interest to report.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.